Comparison · NCT04182204-4fa43e49
Stage 2: R-GemOx vs Stage 2: Pola-R-GemOx: Stage 2: Number of Participants With PN
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Stage 2: R-GemOx vs Stage 2: Pola-R-GemOx: Stage 2: Number of Participants With PN. Trial comparisons, record NCT04182204-4fa43e49. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04182204-4fa43e49
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.288 | 0.216 | 0.373 | wilson | |
| Risk in group 2 | 0.57 | 0.484 | 0.653 | wilson | |
| Risk difference, group 1 minus group 2 | -0.282 | -0.392 | -0.161 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.505 | 0.369 | 0.691 | log | |
| Odds ratio, group 1 over group 2 | 0.305 | 0.181 | 0.514 | log | |
| Number needed to treat, for one fewer participant with the outcome on Stage 2: R-GemOx than on Stage 2: Pola-R-GemOx | 3.54 | 2.55 | 6.21 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Stage 2: R-GemOx | R-GemOx: Participants received rituximab, 375 mg/m\^2, IV on Day 1, followed by gemcitabine, 1000 mg/m\^2, IV and oxaliplatin 100 mg/m\^2, IV on Day 2 of each 21-day cycle for up to 8 cycles. | 36 | 125 | OG000 |
| Group 2 | Stage 2: Pola-R-GemOx | Participants received rituximab, 375 mg/m\^2, IV, followed by polatuzumab vedotin, 1.8 mg/kg, IV on Day 1 of each 21-day cycle. Participants also received gemcitabine, 1000 mg/m\^2, IV followed by oxaliplatin 100 mg/m\^2, IV on Day 2 of each 21-day cycle for up to 8 cycles. | 73 | 128 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Stage 2: Number of Participants With PN
- Description
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Participants receiving polatuzumab vedotin may develop PN, including peripheral sensory and/or motor neuropathy. Symptoms included hypoesthesia, hyperesthesia, paresthesia, dysesthesia, discomfort, a burning sensation, weakness, gait disturbance, loss of balance, orthostatic hypotension, syncope, or neuropathic pain.
- Time frame
- From treatment initiation until 90 days after the last dose of study drug or initiation of NALT (approximately 10.6 months)
- Population
- Safety-evaluable population included all participants who received any amount of any study drug (regardless of the stage).
Source ClinicalTrials.gov
Trial
- Title
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- NCT number
- NCT04182204
- Phases
- PHASE3
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Polatuzumab Vedotin, Rituximab, Gemcitabine, Oxaliplatin
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2025-12-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04182204?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04182204-4fa43e49